Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Autor: Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Carol Ann Huff, Murali Janakiram, Yi-Hsuan Liu, Kevin C. De Braganca, Nicole Lodowski, Jennifer Sander, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Zaina P. Qureshi, Krina K. Patel

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

IntroductionChimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtage

Externí odkaz: https://doaj.org/article/7ded4f0c8f524a62a65d7cce93bbdc68

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Autor: Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel

Publikováno v: Blood, 141(3), 219-230. American Society of Hematology
Cohen, A D, Mateos, M-V, Cohen, Y C, Rodriguez-Otero, P, Paiva, B, van de Donk, N W C J, Martin, T, Suvannasankha, A, de Braganca, K C, Corsale, C, Schecter, J M, Varsos, H, Deraedt, W, Wang, L, Vogel, M, Roccia, T, Xu, X, Mistry, P, Zudaire, E, Akram, M, Nesheiwat, T, Pacaud, L, Avivi, I & San-Miguel, J 2023, ' Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents ', Blood, vol. 141, no. 3, pp. 219-230 . https://doi.org/10.1182/blood.2022015526

B-cell maturation antigen (BCMA)–targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f92ce30d0add10cbca7efbb557b434a
https://doi.org/10.1182/blood.2022015526

Cilta-Cel Efficacy and Safety in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Autor: Attaya Suvannasankha, Maria-Victoria Mateos, Yael C Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W.C.J. van de Donk, Thomas Martin, Adam D. Cohen, Christina Corsale, Jordan M Schecter, Kevin C. De Braganca, Carolyn C Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel

Publikováno v: Transplantation and Cellular Therapy. 29:S395-S396

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::900a3994967c55c9396083382e214a7f
https://doi.org/10.1016/s2666-6367(23)00596-1

Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents

Autor: Adam D, Cohen, Maria-Victoria, Mateos, Yael C, Cohen, Paula, Rodriguez-Otero, Bruno, Paiva, Niels W C J, van de Donk, Thomas G, Martin, Attaya, Suvannasankha, Kevin C, De Braganca, Christina, Corsale, Jordan M, Schecter, Helen, Varsos, William, Deraedt, Liwei, Wang, Martin, Vogel, Tito, Roccia, Xiaoying, Xu, Pankaj, Mistry, Enrique, Zudaire, Muhammad, Akram, Tonia, Nesheiwat, Lida, Pacaud, Irit, Avivi, Jesus, San-Miguel

Publikováno v: Blood.

B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADC), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5661c6d2a466eff783e6c2340d37dd1c
https://pubmed.ncbi.nlm.nih.gov/36095849

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2

Autor: Muhammad Akram, Andrzej Jakubowiak, Nikoletta Lendvai, Samir Parekh, Bertrand Arnulf, H. Einsele, Carolyn C. Jackson, D. Geng, Claire Li, Kevin C. De Braganca, Nwv Donk, MJ Carrasco-Alfonso, Deepu Madduri, Adam B. Cohen, Jaime Gállego Pérez-Larraya, M.V. Mateos, Enrique Zudaire, Yunsi Olyslager, Helen Varsos, Bianca Santomasso

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S263-S264 (2021)

Objective Cilta-cel (JNJ-68284528) is a chimeric antigen receptor T cell (CAR-T) therapy with two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies designed to confer high avidity binding. CARTITUDE-2 (NCT04133636) is a phase 2, mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c820d579ab3bba4423aacbfe80d40b
http://www.sciencedirect.com/science/article/pii/S2531137921005940